Frequently Asked Questions
- How will WIPO Re:Search help advance R&D for neglected diseases, malaria, and tuberculosis?
- What does the database contain?
- How do I access the database?
- Who are the current Providers that have contributed to the WIPO Re:Search Database?
- Who is eligible to access the resources of WIPO Re:Search?
- What criteria will be used in deciding whether a potential licensee can have access and, ultimately, a license?
- What types of intellectual property are relevant/needed for WIPO Re:Search?
- Once intellectual property is provided to the WIPO Re:Search database, can the owner withdraw it?
- Is the intellectual property provided on an exclusive basis?
In WIPO Re:Search, several of the world’s leading research and development-based pharmaceutical companies and other research and academic institutions are promoting research and development for new drugs, vaccines, and diagnostics for neglected tropical diseases-- including tuberculosis and malaria --by voluntarily making available for licensing intellectual property assets and other resources.By providing a searchable, public database of available intellectual property assets and resources, WIPO Re:Search facilitates new partnerships that will support organizations that conduct research on treatments for neglected tropical diseases.The WIPO Re:Search database provides information on the intellectual property available for licensing from a Provider, as well as services and other technology or materials not necessarily protected by intellectual property. Researchers working to advance the development of new drugs, vaccines, or diagnostics for neglected tropical diseases are encouraged to explore the database for any assets that can help advance their work.
We encourage researchers who use the assets in the database to share their findings and contribute back to the database thereby increasing the body of knowledge available to the research community. The goal is for the database to act as a catalyst to stimulate further sharing of research and ultimately become a living repository of research findings in the field.
The intellectual property made available in WIPO Re:Search goes beyond patents and patent rights. Providers are encouraged to provide the following additional data types:
- Screening or Hits Data
- Hit-to-Lead Data
- Lead Series Optimization
- Pre-Clinical Candidate
- Clinical Candidate
- Marketed Product
- Enabling Technology Platform
- Intellectual Property
- Diagnostic Tool
- Vaccine Technology
- New Biological Entity
- Other Types of data or services
At present, the database does not cover all of the above categories, but has significant contributions in the area of intellectual property, screening or hits data, pre-clinical candidate data and enabling technology platforms, as well as access to pharmaceutical company facilities by qualified researchers. The database is continually being expanded and refined with additional contributions from new and existing Providers of intellectual property and know-how. Please search the database for specific inquiries as it is continually updated and expanded.
You can freely search the database. Once you identify information that you would like to explore further, you can submit a request for additional information through the Partnership Hub, or as the case may be, directly with the Provider.
A list of the current Providers is available.
Anyone can freely access the database to browse or search the information. The WIPO Re:Search consortium is a voluntary endeavor, open to all bona fide private and public entities for the purpose of developing new drugs, vaccines, or diagnosticsfor neglected tropical diseases, malaria, and tuberculosis.
Access to further assistance is handled through the Partnership Hub.
What criteria will be used in deciding whether a potential licensee can have access and, ultimately, a license?
Access to further information and inquiries into Provider materials beyond the information provided on this website and the WIPO Re:Search Database are managed through the Partnership Hub (unless otherwise specified by a Provider). In accordance with the Guiding Principles, licensing agreements are individually negotiated between Providers and Users. The Partnership Hub is where licensing and research collaboration opportunities, networking possibilities, and some potential funding resources will be made available. All subsequent discussions toward a licensing agreement and preliminary arrangements (confidentiality and other types of agreements) are handled directly between the Provider and potential User, with facilitation and assistance from BVGH and WIPO as may be appropriate in a given case.
- Compounds with neglected tropical disease data: Compounds with some form of known activity, either against a validated drug target from a neglected tropical disease or from a phenotypic or replication screen for a neglected tropical disease, are valuable resources. Hits that are beyond the scope of ongoing work at the original screening company can be farmed out to other researchers for follow up or hits can be used as a starting point for testing compounds in related neglected tropical diseases with overlapping therapeutic targets. Screening data from relevant model organisms for neglected diseases or closely related veterinary diseases are also highly relevant.
- Compound libraries from other projects: Neglected tropical diseases, malaria, and tuberculosis, share many biological pathways and potential drug targets with other diseases or conditions. For example, pathways and protein classes with known or potential neglected tropical disease application include:
- DNA damage
- Nucleic acid synthesis (e.g., purine and pyrimidine synthesis or salvage pathways, DNA winding/unwinding enzymes, and DNA/RNA polymerases, etc.)
- Lipid biosynthesis (e.g., fatty acid, triglyceride, phospholipid, and sterol synthesis enzymes)
- Energy metabolism (e.g., electron transport chain, ATP synthase)
- Ion channels (e.g., glutamate-gated chloride channels, acetylcholine-gated chloride channels, calcium channels, calcium activated chloride channels, cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel)
- Protein synthesis (e.g., ribosome subunits)
- Proteases (e.g., cysteine, serine, aspartyl, metallo, and threonine proteases)
- Analog libraries and structure-activity relationship series that may have been identified or developed through the lead optimization process are important to assess as selective inhibitors of neglected tropical disease enzymes or other targets over human host targets. Other compounds are also of interest, such as natural product libraries, where the target may not be known.
- Other compounds of potential interest in neglected tropical disease research. Compounds and associated data which have the potential to be useful in neglected tropical disease, malaria, or tuberculosis research, but for which no obvious target mechanism of action has yet been identified, may be made available for further research.
- Technologies for drug target identification and validation, high throughput screening, or complex dataset analysis: Beyond chemical compounds or other agents that can serve directly as therapeutics, technologies that can be used to identify and/or validate drug targets, improve screening, or analyze complex screening or structural prediction datasets have the potential to contribute to new neglected tropical disease drug development. Technologies for drug target identification and validation include genomics and proteomics based systems, conditional knockout technologies or proprietary vectors, RNAi/siRNA or other antisense silencing techniques, unique animal models, and novel electroporation or other transfection techniques. High throughput screening protocols have adapted and optimized biological interaction or activity assays to evaluate large numbers of test agents. These can include novel organism strains with reporter genes, data capture/analysis technologies including plate reader technologies, liquid handling, and data collection, storage, and analysis software. In addition to software for large and often complex high throughput screening analysis, software for structural prediction, molecular modeling and docking, or other analytical techniques is also valuable.
- Technologies for drug formulations or drug administration: In the resource- poor countries where the majority of neglected diseases occur, the shelf life of drugs can be affected by extreme environmental conditions. Technologies that improve stability of drugs and extend shelf life at in high temperatures and high humidity would add significant value. Also, the limited training of health care staff necessitates that drug administration and dosing be straightforward and easy to understand. Oral formulations for standard adult therapeutics, rapidly dissolving/dispersible formulations for children, or novel formulations or administration methods that are needle free and simplify patient treatment are all valuable.
- Existing or novel adjuvants. The neglected diseases for which vaccines are not available are often biologically complex relative to other vaccine preventable diseases. Therefore, access to the widest possible range of adjuvants, existing and novel, is important to fully explore the potential for vaccination against these diseases.
- Viral, DNA, or bacterial vaccine vectors. There are numerous viral, DNA, and bacterial vaccine vectors in development for both neglected and non-neglected disease applications. Vectors currently in development for cancer, veterinary use, or other infectious diseases are all relevant.
- Vaccine delivery technologies. Because most vaccines for neglected diseases will be delivered in low resource settings, vaccine delivery technologies that are needle free or simple to administer by minimally trained healthcare workers are preferable.
- Cold chain/stability solutions for vaccines. Delivery of vaccines in low resource settings of the developing world is challenging. Technologies that can maintain the cold chain without electricity to facilitate vaccine delivery or technologies that stabilize vaccines for storage and transportation at variable temperature ranges are both valuable for neglected diseases vaccine development.
- Clinical trial data or patient samples from neglected disease vaccines in development. For many neglected diseases, the human immune response to infection is poorly understood. This creates challenges in the design of effective vaccines. Data from completed clinical trials for neglected disease vaccines are valuable to inform future trial design. Human samples from both vaccinated and control patients that may be generated during the course of clinical trials are also important resources for scientists interested in identifying surrogate markers of immune protection.
- Validated biomarkers. By sharing biomarker data for neglected diseases, the likelihood that biomarkers will be evaluated on multiple diagnostic technology platforms is increased.
- Detection methods. Independent of the format of a diagnostic, the results need to be clear and understandable for a minimally trained healthcare worker. Detection methods that amplify signals, simplify readout, or provide opportunities for data storage/transmission are all relevant for neglected disease diagnostics.
- Platform technologies. Diagnostics can be built on multiple technology platforms, ranging from complex laboratory-based assay platforms to simple devices that can be used in local, remote settings. Sharing access to a broad range of technologies and know-how related to these technologies provides an opportunity to adapt existing technologies to diagnose neglected diseases or the opportunity to validate novel platform technologies using a neglected disease as a test case. Relevant diagnostic technologies include, but are not limited to:
- Nucleic acid amplification
- Lateral flow devices
- Microfluidic devices
- Other emerging technologies
- Patient samples from neglected disease diagnostics in development. In order to evaluate new diagnostic technologies, researchers need access to samples from patients affected by the disease. Providing access to patient samples from previous clinical evaluations of diagnostics or other clinical trials involving the neglected disease are valuable resources for new diagnostic evaluation.